ALZN
Alzamend Neuro Inc
NASDAQ: ALZN · HEALTHCARE · BIOTECHNOLOGY
$1.21
-0.82% today
Updated 2026-10-30
Market cap
$6.27M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.30
Dividend yield
—
52W range
$1 – $3
Volume
0.1M
WallStSmart proprietary scores
28
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C4.8
Quality
C3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-58.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →252 stocks currently score above 75
Price targets
Analyst target
$26.00
+2048.76%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -58.66 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-1.14M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-14.88M | $-9.95M | $-4.51M | $-8.77M | $-3.03M |
| EPS | — | — | — | — | $-2.30 |
| Free cash flow | $-8.92M | $-8.42M | $-6.87M | $-8.07M | $-1.14M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Alzamend Neuro Inc trades at $1.21. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -58.66, it sits in the distress.
Frequently asked questions
What is Alzamend Neuro Inc's stock price?
Alzamend Neuro Inc (ALZN) trades at $1.21.
Is Alzamend Neuro Inc overvalued?
Alzamend Neuro Inc carries a Smart Value Score of 28/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Alzamend Neuro Inc (ALZN)?
The 12-month analyst consensus target is $26.00, about 2048.8% above the current $1.21. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Alzamend Neuro Inc's Altman Z-Score is -58.66, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-322.36%
Beta0.27
50D MA$1.60
200D MA$1.53
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—